wherein R is selected from H and an acyl group containing from 6 to 24 carbon atoms with the proviso that two of the R groups are H, and

ii) a fatty acid with 6 to 24 carbon atoms, the acyl group of the fatty acid being saturated or unsaturated,

i) and ii) being present in the adjuvant in such concentration that the combination of

i) and ii) elicits an immune response when administered to an animal.

65. (New) An adjuvant for use in a vaccine, the adjuvant consisting essentially of

i) a monoglyceride preparation having at least 80% w/w monoglyceride content and at the most 1% w/w of free fatty acid, the monoglyceride having the formula



wherein R is selected from H and an acyl group containing from 6 to 24 carbon atoms with the proviso that two of the R groups are H,

ii) a fatty acid with 6 to 24 carbon atoms, the acyl group of the fatty acid being saturated or unsaturated

i) and ii) being present in the adjuvant in a weight ratio of from 0.1/50 to 50/1 so that the combination of i) and ii) elicits an immune response when administered to an animal.

66. (New) An adjuvant according to claim 64 or 65, wherein the vaccine contains an antigen component.

67. (New) An adjuvant according to claim 64 or 65, wherein the content of monoglyceride in the monoglyceride preparation i) is at least 90%.

68. (New) An adjuvant according to claim 64 or 65, wherein the content of monoglyceride in the monoglyceride preparation i) is at least 95%.

69. (New) An adjuvant according to claim 64 or 65, wherein the acyl group of the monoglyceride in the monoglyceride preparation i) contains from 8 to 20 carbon atoms.

70. (New) An adjuvant according to claim 64 or 65, wherein the acyl group of the monoglyceride in the monoglyceride preparation i) contains from 14 to 20 carbon atoms.

E1 cont

71. (New) An adjuvant according to claim 64 or 65, wherein the acyl group of the fatty acid ii) contains from 8 to 20 carbon atoms.

72. (New) An adjuvant according to claim 64 or 65, wherein the acyl group of the fatty acid ii) contains from 14 to 20 carbon atoms.

73. (New) A vaccine composition comprising an adjuvant according to claim 64 or 65 and an immunogenic quantity of an antigen component.

74. (New) A vaccine or antigen composition according to claim 73, wherein the antigen component is capable of causing the formation of an antibody in animals including humans and marine animals.

75. (New) A vaccine composition according to claim 73, wherein the antigen component is selected from the group consisting of antigens from pathogenic and non-pathogenic bacteria, viruses, parasites and tumor cells.

76. (New) A vaccine composition according to claim 73 further containing an aqueous medium.

77. (New) A vaccine composition according to claim 73 containing, in 100g of the final composition:
from 0.01 to 90 g of the antigen component
from 1 to 20 g of the monoglyceride preparation i)
from 1 to 20 g of the fatty acid ii)
from 0.01 to 99 g of water
from 0.01 to 99 g of PBS or saline
and optionally one or more additional adjuvants or excipients.

78. (New) A vaccine composition, according to claim 73, wherein the composition comprises additional pharmaceutical excipients selected from the group consisting of preservatives, osmotic pressure controlling agents, pH-controlling agents, organic solvents, enzyme inhibitors, water absorbing polymers, absorption promoters and anti-oxidative agents.

79. (New) A vaccine composition according to claim 73, wherein the composition comprises additional adjuvants.

80. (New) A vaccine composition according to claim 73, wherein the composition is in a form suitable for parenteral or mucosal administration.

81. (New) A vaccine composition according to claim 80, wherein the composition is in a form suitable for administration to the mucosa of the nose, mouth, vagina, rectum or intestine.

82. (New) A vaccine composition according to claim 80, wherein the composition is in a form suitable for administration to the mucosa of the nose.

83. (New) A vaccine composition according to claim 73, wherein the antigen component is selected from the group consisting of diphtheria toxoid, influenza virus, and rotavirus.

84. (New) A vaccine composition according to claim 73, wherein the content of monoglyceride in the monoglyceride preparation i) of the adjuvant is at least 90%.

85. (New) A vaccine composition according to claim 73, wherein the content of monoglyceride in the monoglyceride preparation i) of the adjuvant is at least 95%.

86. (New) A vaccine composition according to claim 73, wherein the acyl group of the monoglyceride in the monoglyceride preparation i) of the adjuvant contains from 8 to 20 carbon atoms.

87. (New) A vaccine composition according to claim 73, wherein the acyl group of the monoglyceride in the monoglyceride preparation i) of the adjuvant contains from 14 to 20 carbon atoms.

88. (New) A vaccine composition according to claim 73, wherein the acyl group of the fatty acid ii) of the adjuvant contains from 8 to 20 carbon atoms.

89. (New) A vaccine composition according to claim 73, wherein the acyl group of the fatty acid ii) of the adjuvant contains from 14 to 20 carbon atoms.

90. (New) A method of enhancing an antibody response in a human or an animal to an antigen, the method comprising administering to the human or animal an anti-body enhancing effective amount of an adjuvant according to any of claims 64 or 65.

91. (New) A method of immunizing a human or an animal, the method comprising administering a vaccine composition according to claim 73.